| Segment Reporting |
The following table contains additional information on our consolidated revenue and net loss, including significant segment expenses: | | | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended June 30, | | Six Months Ended June 30, | | | | (In thousands) | 2026 | | 2025 | | 2026 | | 2025 | | | | Product revenue, net - U.S. | $ | 40,917 | | | $ | 12,151 | | | $ | 59,768 | | | $ | 20,877 | | | | | Product revenue, net - Rest of world | 3,828 | | | 304 | | | 5,723 | | | 304 | | | | | PK activator (PYRUKYND®/AQVESME™) direct expenses - research and development | (25,849) | | | (29,809) | | | (49,754) | | | (51,130) | | | | | Compensation and related expenses - research and development | (30,352) | | | (27,594) | | | (67,141) | | | (60,584) | | | | | Total selling, general and administrative expenses | (51,547) | | | (45,869) | | | (99,851) | | | (87,396) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Other segment items* | (37,700) | | | (21,203) | | | (48,559) | | | (23,380) | | | | | Net loss | $ | (100,703) | | | $ | (112,020) | | | $ | (199,814) | | | $ | (201,309) | | | |
*Other segment items primarily include cost of sales, other research and development expenses, and interest income.
|